Hunterian Medicine® Licenses Inscripta’s MAD7™ Nuclease to Advance Gene Editing Research and Development
BOULDER, Colo. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Inscripta, Inc., the digital genome engineering company, today announced that it has granted a non-exclusive license to Hunterian Medicine®, a gene-editing and gene therapy company, for access to the …